MedTrace Logo

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06487156 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 404

Last updated 2026-01-27

No results posted yet for this study

Summary

The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Nivolumab + ipilimumab

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-11
Primary Completion
2030-10-11
Completion
2030-10-11
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487156 on ClinicalTrials.gov